Results 141 to 150 of about 4,663 (174)
Some of the next articles are maybe not open access.
The Philosophy of Graves' Ophthalmopathy
Orbit, 2005When asked what has been my philosophy of Graves' ophthalmopathy in the last 25 years in the process of caring for patients with this disease and doing clinical research, I identified in hindsight three major guiding principles. The first is a multidisciplinary approach to the disease.
openaire +1 more source
Radiotherapy for Graves’ ophthalmopathy
2000The interest in the treatment of benign diseases with radiation therapy has grown particularly in the Western part of the world. In 1996, a questionnaire was sent to 1348 institutes worldwide listed in the directory of the Society for Therapeutic Radiology and Oncology asking whether the respondents considered a list of 28 most common benign disorders ...
Kahaly, G.J. +6 more
openaire +2 more sources
The Ophthalmopathy of Graves' Disease
Medical Clinics of North America, 1991Fortunately, most patients with thyroid-related eye disease have mild ocular involvement that spontaneously involutes. Less than 5% of patients with hyperthyroidism will develop sufficiently severe ocular abnormalities that will require surgical intervention. Most patients with thyroid eye findings should be symptomatically managed.
openaire +2 more sources
Rationale of Treatment in Graves Ophthalmopathy
Plastic and Reconstructive Surgery, 2001Graves ophthalmopathy is a chronic and multisystem disorder caused by an autoimmune process, characterized by the presence of antibodies that stimulate a general fibroblastic reaction (thyroid gland and lower extremities), and involves orbital fat tissue and muscles.
CLAUSER, Luigi +3 more
openaire +2 more sources
Immunotherapy for Graves’ ophthalmopathy
Current Opinion in Endocrinology, Diabetes & Obesity, 2014In recent years, immunosuppressive therapy, as an alternative to corticosteroids, has been proposed as novel agents which target the various antigens involved in the pathogenesis of Graves' ophthalmopathy. Although the lack of randomized and controlled studies suggests caution in generalizing results, some data show interesting results.Potential ...
openaire +2 more sources
Management of Graves' ophthalmopathy
Nature Clinical Practice Endocrinology & Metabolism, 2007Management of Graves' ophthalmopathy is preferably done in a multidisciplinary setting. Smoking is associated with worse disease outcome. (131)I therapy for hyperthyroidism can also worsen ophthalmopathy, especially if administered during active disease or to patients who smoke or have severe hyperthyroidism, or those with high levels of TSH-receptor ...
openaire +2 more sources
Introduction to Graves’ ophthalmopathy
2000Although the pathogenesis of Graves’ ophthalmopathy is incompletely understood, we have a rather good insight as to how the pathologic changes in the orbit cause (in a mechanical way) the clinical characteristics. To better understand this it is important to be acquainted with the anatomy of the orbit.
Prummel, M.F. +4 more
openaire +2 more sources
Epidemiology and Prevention of Graves' Ophthalmopathy
Thyroid, 2002Graves' ophthalmopathy is clinically relevant in approximately 50% of patients with Graves' disease, severe forms affecting 3%-5% of patients. Two age peaks of incidence are observed in the fifth and seventh decades of life, with slight differences between women and men.
Wiersinga, Wilmar M., Bartalena, Luigi
openaire +3 more sources
Immunosuppressive treatment of Graves' ophthalmopathy
Trends in Endocrinology & Metabolism, 1990Steroids or orbital irradiation are effective in approximately 60% of patients with severe Graves' ophthalmopathy; the improvement of proptosis and extraocular muscle dysfunction, however, is limited. Better results are obtained by the combination of orbital irradiation and systemic steroids.
openaire +5 more sources
Tocilizumab in Graves ophthalmopathy
Medicina Clínica (English Edition), 2020Gemma, Garreta Fontelles +2 more
openaire +2 more sources